{
  "id": "PLUVICTO8",
  "type": "trial",
  "studyCompletion": "2026-11",
  "name": "(ConfigType=trial) A prescription medicine used to treat men with PSMA+ metastatic castration-resistant prostate cancer (mCRPC).",
  "description": "PLUVICTO is a radioligand therapy (RLT). RLT is a different type of radiation therapy that is injected and that targets a biomarker called PSMA, which is present on many prostate cancer cells and also some healthy cells. This means it is designed to find and attack PSMA+ cells, including cancer cells.",
  "link": "https://us.pluvicto.com/support/faqs",
  "patientsFilter": {
    "filter": {
      "must": [
        {
          "attributes.gender": {
            "eq": "male"
          }
        }
      ]
    }
  },
  "variables": [
    {
      "id": "dob",
      "definition": {
        "fulfillment": {
          "queries": [
            {
              "alias": "PATIENT",
              "query": {
                "from": "patient",
                "show": [
                  "attributes.dob"
                ],
                "dedup": true
              }
            }
          ]
        }
      },
      "display": "Patient's date of birth",
      "usingAi": false
    }
  ],
  "criteria": [
    {
      "id": "criteria_male",
      "type": "inclusion",
      "title": "Gender is male",
      "expression": "gender",
      "subCriteria": [
        {
          "id": "gender",
          "title": "Gender is male",
          "description": "Gender is male",
          "expression": "variables.gender.value[].attributes.gender|[0]== `male`",
          "explainability": {
            "displayValue": "variables.gender.value[].attributes.gender|[0]"
          }
        }
      ]
    }
  ]
}

